Bringing Discoveries to Commercialization
Genezen Labs Secures Funding to Establish Fishers Presence

Genezen Labs Secures Funding to Establish Fishers Presence

Friday, January 8, 2021

A Fishers-based cell and gene therapy company has received a capital infusion it says will fuel growth in central Indiana. Genezen Laboratories Inc., which manufactures viral vectors used to treat rare diseases and cellular therapies to treat cancer, says the growth equity investment from Massachusetts-based Ampersand Capital Partners will be used to complete construction on its 25,000-square-foot production facility and create dozens of jobs. Read More…

Center Taps Into ‘Huge’ Life Sciences Assets

Friday, January 8, 2021

The center will serve as a biomedical incubator and is designed to help move discoveries from the laboratory to the marketplace. It is located in the former Methodist Research Institute at IU Health Methodist hospital near the IUPUI campus. Singh says its is a unique entrepreneurial space. “It is not simply a building where you incubate your startup. It’s a collaborative ecosystem bringing entrepreneurs, life science experts and investors together.” In addition to the medical school, IU Health and the Indiana Clinical and Translational Sciences Institute are involved. It will also partner with IU School of Medicine’s Industry Collaboration Program. Click here to read more.

10104362_G

ICBI Inaugural Ceremony

Friday, January 8, 2021

Inaugural ceremony of the Indiana Center for Biomedical Innovation (ICBI) on March 15th at the Methodist hospital Noyes Pavillion. The newly developed center provides a platform for academic entrepreneurs to translate their discoveries into commercial products for health care and ultimately, improved patient care.

icbi-event

ICBI Advisory Council Reviews First Round of Applications for Technology Enhancement Award

Friday, January 8, 2021

On February 5, 2016, the Advisory Council of Indiana Center for Biomedical Innovation (ICBI) participated in first meeting for review of research proposals from Indiana University School of Medicine entrepreneurs for the “Technology Enhancement Award (TEA). TEA is a new CTSI supported mechanism to support translation and commercialization of innovative technologies. The Advisory Council consisting of leaders and entrepreneurs in life sciences arena serves as an important resource for a wide range of scientific, technical, clinical, business, legal, regulatory and other guidance to the scientists associated with IUSM and ICBI.

Four new projects were presented by principle investigators including Drs. Milan Radovich, Alexander B. Niculescu, Yvonne Lai and Jian-Ting Zhang. The highly interactive two hour session provided valuable feedback and insight to the presenters on their respective project. The Advisory Council members include, Dr. Mervin Yoder, Dr. Eric Woods, Mr. Harry Gonso, Dr. Jaswant Gidda, Dr. Jeremy Schieler, Dr. Kenneth H Carlson, Dr. Mohan Tatikonda, Dr. Milan Radovich, Dr. Raymond Kauffman, Dr. Scott Sheehan, Mr. Chad Pannucci, Dr. Jeff Kline and Dr. Joseph Trebley, Dr. Viren Sarin, Dr. Todd Saxton, Mr. David Broeker and Dr. Alan Wright.

The outcome of the review and awardees will be announced on March 15, 2016.

DSC_0156

Funding for Repurposing Drugs through CureAccelerator

Friday, January 8, 2021

Indiana CTSI and Indiana Center for Biomedical Innovation  (ICBI) has established a MOU with CureAccelerator to provide grant funding for repurposing of drugs discovered at IUSM and other CTSI affiliated Universities.  Cure Accelerator is a Chicago based non-profit organization, founded and managed by Cures Within Reach. It supports repurposing of drugs, devices and medicine from academia that has the potential to meet the needs of patients worldwide. CTSI- affiliated faculty are eligible to apply for this grant.

View Full Article on Cure Accelerator 

homeB1

Branis Pesich

Friday, January 8, 2021

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Anya Day, MPH

Friday, January 8, 2021

Allison Bryan-Jungels, MS, CHES

Friday, January 8, 2021

Randy Hountz

Friday, January 8, 2021

Theresa Walunas, PhD

Friday, January 8, 2021